What is Genfit?
Founded in 1999 and headquartered in Loos, Hauts-de-France, Genfit has established itself as a specialized entity focused on addressing significant unmet medical needs. The company operates at the intersection of biotechnology and pharmaceutical development, prioritizing the creation of innovative treatments and diagnostic tools. Its market position is defined by a rigorous scientific approach to metabolic and inflammatory conditions, allowing it to navigate the high-stakes environment of drug discovery and commercialization with a focus on patient outcomes and clinical efficacy.
How much funding has Genfit raised?
Genfit has raised a total of $703M across 13 funding rounds:
Share Placement
$15.5M
Share Placement
$5.4M
Share Placement
$22.7M
Share Placement
$36.6M
Share Placement
$48.2M
Debt
$194.5M
Stock Offering
$155.4M
Debt
$13.3M
Debt
$200M
Share Placement (2013): $15.5M, investors not publicly disclosed
Share Placement (2014): $5.4M, investors not publicly disclosed
Share Placement (2014): $22.7M, investors not publicly disclosed
Share Placement (2016): $36.6M, investors not publicly disclosed
Share Placement (2016): $48.2M, investors not publicly disclosed
Debt (2017): $194.5M, investors not publicly disclosed
Stock Issuance/Offering (2019): $155.4M, investors not publicly disclosed
Debt (2021): $13.3M led by The French Government
Debt (2025): $200M supported by HealthCare Royalty Management
Key Investors in Genfit
HealthCare Royalty Management
HealthCare Royalty is a specialized investment firm that provides capital solutions to biopharmaceutical companies through the acquisition of royalty interests and tailored financing arrangements.
YA Global Master SPV Ltd
An investment entity that has historically participated in share placement rounds to support the growth and capital requirements of emerging biopharmaceutical firms.
OSEO
A public investment institution focused on supporting innovation and industrial development through strategic debt and financing initiatives for high-potential companies.
What's next for Genfit?
With the recent capital injection, Genfit is well-positioned to accelerate its strategic initiatives, particularly as it navigates the transition toward commercial-stage operations. The firm's focus remains on optimizing its therapeutic portfolio and enhancing its diagnostic capabilities to maintain a competitive edge in the global life sciences market. By utilizing non-dilutive financing and strategic partnerships, Genfit aims to sustain its operational momentum, ensuring that its clinical assets reach critical milestones while maintaining the flexibility required to adapt to evolving market demands and regulatory landscapes.
See full Genfit company page
